Clinical Trials Logo

Filter by:
NCT ID: NCT02303431 Completed - Clinical trials for Venous Thromboembolism

Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study

Start date: November 5, 2014
Phase: Phase 1
Study type: Interventional

This is the first evaluation of edoxaban in pediatric subjects. In this Phase 1 study, a single dose of edoxaban will be given to pediatric subjects who require anticoagulant therapy to see what the body does to the drug (pharmacokinetics) and what the drug does to the body (pharmacodynamics), and to compare if these effects are similar to those observed in adults.

NCT ID: NCT02303093 Completed - Clinical trials for Primary and Secondary Immunodeficiency and Other Conditions Requiring Regular Administration of Octagam 5% or 10% IVIG

Non-Interventional Study on the Tolerability and Efficacy of IVIG

GAM 10-06
Start date: August 1, 2011
Phase:
Study type: Observational

Non-Interventional Study on the Tolerability and Efficacy of octagam® 10%

NCT ID: NCT02303028 Completed - Solid Tumors Clinical Trials

Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid Tumours

TOPAZ
Start date: March 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I, dose escalation study where topotecan will be administered at lower doses given more frequently on a prolonged schedule (low dose metronomic; LDM), in combination with pazopanib administered in a specific dose range. The maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) will be evaluated for LDM topotecan in combination with pazopanib in children with recurrent or refractory solid tumours. Pharmacokinetic and pharmacodynamic studies will be conducted to further define the exposure to and activity of LDM topotecan in combination with pazopanib.

NCT ID: NCT02303002 Completed - Clinical trials for Glabellar Frown Lines

Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines

Start date: December 2014
Phase: Phase 2
Study type: Interventional

This is a safety and efficacy study of botulinum toxin type A in subjects with glabellar frown lines.

NCT ID: NCT02302807 Completed - Bladder Cancer Clinical Trials

A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]

Start date: January 13, 2015
Phase: Phase 3
Study type: Interventional

This is a Phase III, global, multicenter, open-label, two-arm, randomized, controlled study designed to evaluate the efficacy and safety of atezolizumab compared with chemotherapy in participants with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimen. The anticipated time on study treatment is based on continued clinical benefit, i.e., until disease progression or unacceptable toxicity. The target sample size is 931 participants.

NCT ID: NCT02302378 Completed - Spinal Anesthesia Clinical Trials

Taylor's Approach vs Lumbar Approach for Spinal Anesthesia

Start date: January 2015
Phase: N/A
Study type: Interventional

Spinal anesthesia is a common technique for providing anesthesia for knee joint replacement surgery. The investigators wish to demonstrate that using a lower approach to spinal anesthetic (Taylor's approach of L5-S1) causes less low blood pressure while still providing adequate anesthesia for knee joint replacement surgery than a higher approach (L3-L4).

NCT ID: NCT02302131 Completed - Clinical trials for Pulmonary Valve Malfunction

Pulmonic SAPIEN XT THV

Pulmonic XT
Start date: November 2014
Phase: N/A
Study type: Observational [Patient Registry]

Multi-center, Observational Registry with Retrospective Enrollment and Prospective Follow-up. The aim of the registry is to document the feasibility and safety of implanting an Edwards SAPIEN XT transcatheter heart valve in the pulmonic position.

NCT ID: NCT02301624 Completed - Clinical trials for Refractory Generalized Myasthenia Gravis

Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis

Start date: November 12, 2014
Phase: Phase 3
Study type: Interventional

To evaluate the safety and efficacy of eculizumab in the treatment of refractory generalized myasthenia gravis (gMG) as an extension study for the participants who previously completed Study ECU-MG-301(NCT01997229).

NCT ID: NCT02301234 Completed - Pain Clinical Trials

Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007

Start date: March 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate the efficacy, safety, and tolerability of fulranumab as adjunctive therapy compared with placebo in participants with signs and symptoms of osteoarthritis of the hip or knee that are not adequately controlled by current pain therapy.

NCT ID: NCT02301143 Completed - Clinical trials for Pancreatic Neoplasms

Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)

LAPACT
Start date: April 21, 2015
Phase: Phase 2
Study type: Interventional

This clinical study is in subjects who are 18 years old or older with locally advanced pancreatic cancer who have not received prior treatment for their pancreatic cancer. The study treats all subjects with nab-Paclitaxel plus gemcitabine for approximately 6 months of treatment. Subjects who complete the treatment will choose, with their treating physicians, what additional treatment should be given: more nab-Paclitaxel plus gemcitabine, Chemoradiation therapy, or surgery to treat the locally advanced pancreatic cancer.